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Abstract
Background/Aims: Delayed graft function (DGF) is associated with adverse outcomes after 
renal transplantation. Bone morphogenetic protein-2 (BMP-2) is involved in both endothelial 
function and immunological events. We compared expression of BMP-2 in epigastric artery of 
renal transplant recipients with immediate graft function (IGF) and DGF. Methods: 79 patients 
were included in this prospective study. Patients were divided in IGF group (64 patients) and DGF 
group (15 patients). BMP-2 expression in intima media (BMP2m) and endothelium (BMP2e) of 
epigastric artery was assessed by immunohistochemistry. Results: Lower intensity of BMP2e 
staining was recorded in DGF compared to IGF. In DGF patients, 93% had no expression of 
BMP2e and 7% had 1st grade expression, compared to 45% and 41% in IGF group, respectively 
(P=0.001) (P<0.001 for no expression and P = 0.015 for 1st grade expression). Patients who had 
BMP2e staining positive had lower odds for DGF (OR 0.059 [0.007, 0.477]) and this remained 
significant even after adjustment for donor and recipient variables, cold ischemia time, and 
immunological matching (OR 0.038 [0.003, 0.492]). Conclusions: Our results demonstrate that 
BMP-2 expression in endothelial cells of epigastric arteries may predict development of DGF.
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IntroductionReported incidence of delayed graft function varies across studies depending on 
definition. When defined by need for dialysis within the first 7 days after transplantation, 
the incidence is up to 70 % [1], especially if donors after cardiac death are used [2]. Delayed 
graft function was found to be an independent risk factor for decreased short and long-term 
graft survival. Additionally, it is associated with increased incidence of acute rejections and 
prolonged hospitalizations [3-5]. For these reasons, the prediction and prevention of DGF 
may improve outcomes of renal transplantation.
Interplay between donor, recipient and procurement factors determines early 
posttransplant course and DGF.  Donor age, size, gender, history of hypertension or diabetes, 
all affect posttransplant outcome. Brain death consequences, hemodynamic instability, as 
well as acute injury induced during kidney recovering and preservation may have significant 
consequences. Recipient factors known to affect posttransplant outcome include age, cardiac 
status, dialysis vintage and hypotension [6]. Faced with aging dialysis population, we are 
also faced with aging population of potential renal transplant recipients with numerous 
comorbidities. However, major focus of investigations in transplantation medicine is 
on potentially modifiable donor risk factors. Recent study suggested the importance of 
recipient factors in addition to donor characteristics [7]. Except for clinical characteristics, 
little is known about recipient factors which may influence DGF. Biomarkers are attractive 
tool for prediction of posttransplant outcome. Pretransplant biopsy is used by some centers 
for estimation of graft quality, but also for prediction of transplant outcome. Recipients’ 
biological materials obtained before transplantation are rarely used for investigations of the 
posttransplant outcome. 
Endothelial cells play a leading role in the response to vascular inflammation. 
Inflammatory stimuli induce endothelial dysfunction and induce a proadhesive endothelial 
phenotype [8], with leukocyte adhesion in a central position, what is also one of the crucial 
steps in development of immunological response after renal transplantation. Thus, research 
into the molecular mechanisms of endothelial cell injury may improve our understanding of 
DGF. 
Bone morphogenetic protein-2 (BMP-2), is a member of the transforming growth 
factor superfamily which was originally detected in cartilage and bone [9]. Recent studies 
demonstrated that vascular endothelial and smooth muscle cells are also a significant source 
of BMP-2 [10, 11]. Bone morphogenetic proteins (BMPs) are important regulators in blood 
vessel formation and vascular disease [12, 13]. Additionally, BMP2 signaling plays a role in 
thymus morphogenesis and T-cell differentiation [14-17]. Although BMP-2 is a well-known 
mediator of vascular calcification [18], its role in the development of atherosclerosis remains 
uncertain. Based on these characteristics we hypothesize a significant role for BMP-2 in renal 
transplantation.
In the present study, we compared an expression of BMP-2 in epigastric artery of renal 
transplant recipients with immediate and delayed graft function, and investigated relation of 
BMP-2 expression with posttransplant outcomes. 
Materials and Methods
Patients and clinical data collection
A prospective cohort study included all patients who received renal transplant at our institution from 
January 2012 to March 2013. The study was approved by the Ethics committee of the University hospital 
center Zagreb and conducted following the Declaration of Helsinki and Istanbul. Patient demographics 
(age, gender), cardiovascular risk factors (smoking, diabetes mellitus, hypertension, body mass index 
category (normal weight, underweight, overweight or obese), dyslipidemia, renal factors (primary disease, 
dialysis vintage, type of dialysis) were collected. Degree of HLA mismatch, PRA and cold ischemia time were 
recorded. 24-hour urine collection was used to determine the creatinine clearance. Clinical data obtained 
for each donor included age, gender, history of hypertension, diabetes mellitus, stroke as a cause of death, 
cardiac resuscitation during intensive care, and serum creatinine level. Control group included 16 non-
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diabetic patients, nephrectomized due to localized renal cancer (T1, N0, M0), with serum creatinine within 
the normal range.  
Assessment of vessel calcification
Pelvic X-rays obtained at the day of transplantation were evaluated by an experienced renal transplant 
surgeon for the presence of vascular calcifications which were classified as present or absent. 
Sample collections and immunohistochemistry
The Gibson incision was used to access to the iliac fossa and expose the iliac vessels. After ligation 
of the epigastric artery, full circumference was resected, as described previously [19-23] and further 
processed in the Clinical Pathology and Cytology department, fixed in formalin, and embedded in paraffin. 
The original specimen slides stained with hematoxylin and eosin were reviewed for the presence of arteries. 
Corresponding paraffin blocks were retrieved and additional slides were prepared from multiple, sequential 
4-μm-thick sections. Anti – human Pro-BMP-2 monoclonal antibody (1:100) (R&D Systems) was used for 
immunohistochemical analysis. Paraffin sections (3-4 μm) of all specimens were deparaffinized in xylene and 
then rehydrated through graded alcohol. Endogenous peroxidase activity was blocked with 0,3 % hydrogen 
peroxide for 10 min. Sections were baked in an oven at 97°C for 20 min. PT link tanks (Dako, Glostrup, 
Denmark) were used to remove paraffin and heat-induced epitope retrieval (EnVision FLEX + K8000, 3 
in1, Solution High pH; Dako). All slides were incubated for 20 min at 97°C and left in buffer (EnVision FLEX 
wash buffer; Dako). Staining was performed using an automated immunostainer (AutostainerLink48; 
Dako). The protocol was as follows: slides were incubated for 10 min in an endogenous block (EnVision 
FLEX + K8000; Dako) and then incubated with antibody for 30 min. Then all sections were incubated for 
30 min in labelled polymer (EnVision FLEX+ K8000; Dako). Each individual stage was followed by buffer 
rinses (EnVision FLEX + K8000; Dako). Staining was visualised using the chromogen 3,3′-diaminobenzidine 
for 10 min, counterstained with hematoxilin (EnVision FLEX+ K8000; Dako) for 10 min and manually 
cover. Immunoreactivity in tumor cells was accessed by grading (0 - 3) and the results were expressed as 
percentage of positive  cells (negative < 10 %, 10-49  % reactive cells – grade 1, 50-74% reactive cells – grade 
2, and more than 75 % reactive cells – grade – 3). A 40x objective was used. Control samples of renal arteries 
were collected after nephrectomy due to localized renal cancer. One section of each artery segment was used 
for the von Kossa stain to assess presence of microcalcifications. For von Kossa staining, tissue was fixed in 
methacarn solution and embedded in paraffin. Sections were then stained using the von Kossa method and 
counterstained with hematoxylin and eosin as described previously [24]. To confirm that von Kossa stain 
yielded the same results (positive or negative) regardless of the resected part of artery, we obtained sections 
of two parts (from each end of the arterial segment). 
Definitions
Expanded criteria donor was defined with following characteristics: a. donor age older than 59 years; b. 
donor age between 50 and 59 years with, additionally two of the following: death caused by cerebrovascular 
accident (CVA); terminal serum creatinine more than 137 µmol/L; history of hypertension [25]. Delayed 
graft function was defined as the need for dialysis after the first week posttransplant. Clinical decision to 
initiate dialysis was made by attending nephrologists. Grafts without need for dialysis after 6 days had 
immediate function. Acute rejection was defined as increase in serum creatinine more than 25% and proven 
by biopsy. Patients were divided in delayed graft function (DGF) group and immediate graft function group 
(IGF) group based on definition of delayed graft function.
Immunosuppression
The maintenance immunosuppressive regimen consisted of mycophenolate mofetil, corticosteroids 
and either tacrolimus (77 patients) or cyclosporine (2 patients). All patients received basiliximab as 
induction therapy. Rejection episodes were treated with steroid bolus therapies.
Statistical analysis 
Statistical analysis was performed using Stata/SE 11.2 for Windows (StataCorp LP, USA). Continuous 
variables were tested for normality of distribution using D’Agostino-Pearson’s test. Differences between 
two groups of normally distributed variables were tested using Student’s t-test while Mann-Whitney U 
test was used for non-normally distributed variables. Differences between categorical variables were 
tested using Fisher’s exact test. Correlations between two variables were tested with Pearson’s test and 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
ity
 o
f Z
ag
re
b 
   
   
   
   
   
   
   
   
   
   
   
 
16
1.
53
.2
22
.5
2 
- 1
0/
30
/2
01
7 
12
:2
6:
07
 P
M
 Kidney Blood Press Res 2016;41:781-793
DOI: 10.1159/000450568
Published online: November 11, 2016
© 2016 The Author(s). Published by S. Karger AG, Basel
www.karger.com/kbr 784
Basic-Jukic et al.: BMP-2 and Delayed Graft Function
Spearman’s rank correlation test, depending on normality of distribution. Logistic regression was used to 
test independent association between a categorical dependent variable and several independent variables 
(i.e. potential confounders). Associations between micro-calcifications (assessed by Von Kossa staining) and 
BMP-2 expression, as well as between micro-calcifications or BMP-2 expression and creatinine or creatinine 
clearance, were tested by Cramér's V statistic. All values were deemed statistically significant for a two-
tailed p<0.05.
Results
General characteristics of patients and comparison according to graft function
Seventy-nine patients undergoing renal transplantation (one receiving graft from a 
living donor) from which epigastric artery samples were taken at the time of surgery, were 
included in this prospective cohort study. Thirty eight percent of donors were male, average 
age was 51±10 (range 23-76) years. Four percent had history of diabetes and 49% had 
history of hypertension at the time of transplantation. Forty percent belonged to the group 
of expanded criteria donors.
Average age of recipient was 51 ± 14 years and 60% were male. The median waiting 
time for kidney transplantation was 2 years (range 0.083 to 7 years). Glomerulonephritis 
(40%) and autosomal dominant polycystic kidney disease (13%) were the most common 
causes of end-stage renal disease. Four recipients had type II diabetes and 8% had history 
of cardiovascular diseases at the time of transplantation. Vascular calcifications determined 
at the time of transplantation by plain X-ray were recorded in 59% of patients. Average BMI 
was 25.3±4.0 kg/m2 (range 15.8-35.3 kg/m2), with 39 (49%) patients with normal weight, 30 
(38%) overweight, 8 (10%) obese and 2 (3%) underweight patients based on WHO (World 
Health Organization) classification. Immunological matching was favorable, with median 
number of 3 miss-matches (MM) (range 1-5). Two patients were sensitized, with PRA 6% 
and 12%. There were no differences in age or sex between 16 control subjects and renal 
transplant recipients with control subjects having normal serum creatinine values.
 
Patients were grouped according to presence of parameters for delayed graft function. 
There were no significant differences in general characteristics of recipients having immediate 
graft function (IGF) and those with delayed graft function (DGF) as shown in Tables 1 and 2. 
Average length of hospitalization in the whole cohort was 12 days (range 7-90 days), with 
interquartile range 10 to 19 days.  Hospitalization was more than two times longer in patients 
with DGF compared to the patients with IGF (median 28 days, interquartile range 18-33 days 
vs. 12 days, 9-16 days, respectively, P<0.001). Patients with DGF had worse graft function at 
one year after transplantation than patients with IGF, with average creatinine clearance of 
40.9±10.6 mL/min compared to 58.5±21.7 mL/min in IGF group (P<0.001) (Figure 1). 
One year after transplantation, 15% of patients with DGF had creatinine clearance <30 
mL/min, compared to 8% of patients from the IGF group (P>0.05), 77% DGF patients had 
creatinine clearance < 50 mL/min, compared to 25% in IGF group (P<0.001), and 51% DGF 
patients had creatinine clearance < 75 mL/min, compared to 8% in IGF group (χ2=8.15, P = 
0.005). None of the DGF patients had creatinine clearance ≥75 mL/min, compared to 16% in 
the IGF group (P>0.05). Patients in the DGF group had significantly higher serum creatinine 
at 1 year, while no difference was observed between the groups regarding overall survival, 
graft loss and acute rejections (Table 3). 
The 1-year recipient survivals in DGF and IGF groups were 100% vs. 96,8% respectively 
(χ2=0.481, P = 1.00), and 1-year death-censored graft survivals were 86,6% vs. 98,4% 
respectively (χ2=1.53, P = 0.095).
Association of BMP2e and BMP2m expression with delayed graft function and 1-year graft 
survival
In 16 control subjects, BMP2 staining was recorded in both endothelial cells and 
muscular cells of medial layer of renal artery. BMP-2e grade 1 staining was recorded in 50%, 
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grade 2 in 19%, while 31% of samples remained negative. A similar pattern was observed 
for BMP-2m with grade 1 staining present in 56%, grade 2 in 13%, and no staining in 31% of 
renal artery samples. None of the controls had grade 3 BMP-2 staining of either endothelium 
or media. 
Expressions of either BMP-2m or BMP-2e in renal transplant recipients did not differ 
regarding gender, smoking status, BMI, or the presence of hypertension, vascular disease or 
hyperlipoproteinemia (HLP), as well as they did not correlate with creatinine or creatinine 
clearance one year after transplatation. The effect of diabetes could not be analyzed due to 
low number of patients with this disease (4 patients). 
Table 1. Donor characteristics according to the immediate (IGF) or delayed graft function (DGF) after transplantation
Table 2. Characteristics of patients with immediate (IGF) and delayed graft function (DGF). TIN, 
tubulointerstitial nephritis; BMI, body mass index; CRP, C-reactive protein; HD, hemodialysis; 
PD, peritoneal dialysis
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in BMP2m expression between DGF, IGF and control group was not found, although there 
was a trend towards lower expression in DGF group compared to the other groups with no 
DGF patients having grades 2 and 3 (Figure 3).
We further wanted to examine if BMP2e and BMP2m expression is an independent 
predictor of graft function in our population. BMP2 expression was dichotomized as positive 
(grades 1, 2 and 3) or negative (no staining) and tested in both unadjusted and adjusted 
logistic regression models. Patients who had BMP2e staining positive (either grade) had lower 
odds for DGF after transplantation (OR 0.059 [0.007, 0.477]) and this remained significant 
even after adjustment for age, sex, BMI, smoking status and history of hypertension and 
DM (all for both donor and recipient), cold ischemia time, MM, and recipient’s time from 
onset of dialysis to transplantation (OR 0.038 [0.003, 0.492]). On the other hand, BMP2m 
positive staining had no effect on graft function after transplantation neither prior (OR 1.41 
[0.45, 4.42]) or after adjustment for multiple covariates (OR 0.86 [0.23, 3.26]). We further 
examined concordance between BMP2e and BMP2m expression. Simultaneous epigastric 
and media layer staining was found in 82.2% of patients, and it was higher in IGF than DGF 
group (87.7% vs. 66.7%, p=0.046). In the IGF group 40.0% of patients had positive staining 
for both BMP2e and BMP2m while only one patient in DGF group (7.1%) had both stains 
positive (p=0.02). Those with positive staining in both endothelium and muscular layer also 
had lower both unadjusted (OR 0.11 [0.01, 0.87]) and adjusted odds for DGF (OR 0.08 [0.01, 
0.95]). Interestingly, not only that BMP2e positive staining was the strongest predictor of 
IGF, none of the other variables were predictors of graft function in our population.
Fig. 1. Graft function at one year after transplantation in 
patients with IGF and DGF. Re-
sults are shown as the percent of patients in four categories of 
creatinine clearance (mL/min). 
IGF-immediate graft function, 
DGF-delayed graft function. 
*Statistically significant diffe-
rence between groups for each category of creatinine clearan-
ce (Pearson's χ2 test, P < 0.01).
Table 3. Selected outcomes in patients with immediate 
(IGF) and delayed graft function (DGF) 
Ninety three percent of DGF pa-
tients had no expression of BMP-2e, 
compared to 45% in IGF group (χ2 = 
11.3, P = 0.001) (Figure 2.). Grade 1 
was found in only 7% of DGF patients 
compared to 41% IGF patients (χ2 = 
6.23, P = 0.013). Lower intensity of 
BMP2e staining was recorded in DGF 
compared to IGF and control patients. 
Grades 2 and 3 were absent in DGF pa-
tients, compared to 13% and 2%, in IGF 
patients (differences not statistically 
significant), respectively, and 19% and 
0%, respectively, in control patients 
(differences not statistically signifi-
cant). Statistically significant difference 
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Patients who had BMP2e positive staining did not have higher odds for 1-year graft 
survival neither before (OR 0.54 [0.09, 3.40]) or after adjustment for multiple covariates (OR 
0.85 [0.04, 20.64]). Similarly, BMP2m positive staining did not influence 1-year graft survival 
neither before (OR 1.35 [0.21, 8.53]) or after adjustment (OR 29.83 [0.41, 2165.96]). Those 
who had both stains positive also did not differ in odds of 1-year graft survival before (OR 
0.31 [0.05, 2.00]) or after adjustment (0.07 [0.001, 4.35].
Von Kossa staining of epigastric arteries
Microcalcifications in the media of epigastric arteries were detected by von Kossa 
Fig. 2. BMP-2 
staining in endothe-lial cells of epigastric 
artery. A. Section of a epigastric artery 
showing no staining 
for BMP. B. Im-
munohistochemical 
staining for BMP-2 
demonstrates strong 
cytoplasmatic im-
munoreactivity in 
endothelial cells 
(X20). C. Enlarge-
ment x 63  D. Distri-
bution of BMP-2 ex-
pression in endothe-lial cells of epigastric 
arteries. IGF-imme-
Fig. 3. BMP-2 
staining in media of epigastric ar-
tery. A. Negative 
immunohistoche-
mical reaction for 
BMP-2 in the media 
of the arterial wall. 
B. Strong cytoplasm 
and nuclear im-
munoreactivity for 
BMP-22 within the 
medial smooth mu-
scle cells (X20). C. 
Enlargement x 63. D. 
Distribution of BMP-
2 expression in the 
media of epigastric 
arteries. IGF-imme-
diate graft function, DGF-delayed graft function. *Statistically significant difference between groups for each 
grade of BMP-2e expression (Pearson's χ2 test, P < 0.05).
diate graft function, DGF-delayed graft function. There was no statistically significant difference between 
two groups.
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staining in only 16,5% of the samples. They were mostly diffusely dispersed in the tissue, 
but in 6 patients numerous calcifications were found. There was no significant difference in 
von Kossa staining between groups (Figure 4). 
Von Kossa staining was not associated with BMP2 staining in endothelium or media 
of epigastric artery. Also, there were no differences in sex, age, smoking status, BMI, or 
the presence of arterial hypertension, vascular disease or HLP. Von Kossa staining did not 
correlate with creatinine or creatinine clearance one year after transplantation.  Of note, 
only four patients had a history of diabetes. All of them had calcifications on plain pelvic 
x-rays, but none had positive von Kossa staining. Iliac artery calcifications on plain pelvic 
x-rays were found in 46 patients (58%) from both groups. Among 46 patients with iliac 
calcifications, von Kossa staining was successfully performed in 45 patients, among which 
9 patients (20%) were positive for micro-calcifications. On the other hand, in patients with 
positive staining for micro-calcifications, 60% (9 out of 15 patients) had calcifications on 
the plain pelvic x-ray. Microcalcifications were also not a predictor of DGF or 1-year graft 
survival in our population (P>0.05).
Discussion
Analysis of recipients’ tissue in combination with donor characteristics seems as an 
interesting possibility for estimation of the posttransplant prognosis.  We have shown 
that renal transplant recipients with high BMP-2 protein expression in endothelial cells of 
epigastric artery have immediate graft function and better one year graft function compared 
to patients without BMP-2 protein expression who suffer from delayed graft function and 
consequently have worse graft function one year after transplantation. 
We did not observe statistically significant influence of donors’ or recipients’ 
characteristics on DGF. Group of patients with DGF more frequently received allografts from 
expanded criteria donors, as well as from donors who were older; more frequently had 
diabetes, and/or hypertension, and also had longer cold-ischemia time. However, none of 
these differences reached statistical significance. Our study may not be sufficiently powered 
to detect statistically significant association between different donor factors and early 
posttransplant allograft function.  Additionally, cold ischaemia time was relatively short 
for the whole cohort, thus decreasing the influence of this parameter on outcomes after 
transplantation. For example, Bronzatto et al. have shown that cold ischemia time >24 hours 
Fig. 4. von Kossa 
staining in vessel wall 
of epigastric artery. A, 
magnification x10, B, 
insert of the vessel wall 
showing diffuse punc-
tuate staining. C, von-
Kossa staining intensitiy 
in control, IGF and DGF 
group was without sta-
tistically significant dif-
ference.
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significantly increase risk for DGF [26], while the longest cold ischemia time in our patients 
was 23 hours. 
In our cohort, male patients previously treated with hemodialysis and with chronic 
glomerulonephritis as primary disease more frequently develop DGF after renal 
transplantation, but without statistical significance. In previous reports in large group 
of patients, distinct characteristics of the recipient were found to increase risk of DGF. 
Maintenance dialysis vintage prior to transplant was found to be perhaps the most important 
contributor [27], followed by obesity and diabetes [28, 29]. Male patients, older than 55 
years, of African-American race, with prolonged waiting-time period, sensitized and those 
who received small-for-size organs all have increased risk for DGF [3, 4, 30-32]. 
As expected, and already demonstrated in previous studies [6], DGF significantly 
prolonged initial posttransplant hospitalization (median 28 days in DGF vs. 12 days in IGF 
group) in our cohort. However, hospitalizations were much shorter in our patients, both in 
the IGF and DGF group probably because of our large centre size and extensive experience, 
with as short hospitalizations as possible. Also, DGF group had significantly worse allograft 
function at one year as determined by serum creatinine and creatinine clearance. However, 
no difference was observed between the groups regarding overall survival, graft loss and 
acute rejections, what is in contrast to findings of a meta-analysis of 34 studies performed 
from 1988 through 2007 which demonstrated that patients with DGF had a 49% pooled 
incidence of acute rejection compared to 35% incidence in non-DGF patients [33]. However, 
we do not perform protocol biopsies in patients with DGF thus some cases of subclinical 
acute rejections might be missed.
Bone morphogenetic proteins (BMP) are pleiotropic growth factors that regulate 
growth, differentiation, chemotaxis and apoptosis of different cell types [34]. They regulate 
kidney development and maintain structure and function in mature kidneys [35]. In kidney 
transplant recipients, only one study of biopsy series investigated the role of BMP7 in early 
fibrogenesis activation after transplantation [36], and our group investigated pattern of BMPs 
expression in kidney graphtectomy specimens, where BMP 4, 6 and 7 were downregulated 
in allografts with interstitial fibrosis and tubular atrophy [37]. 
In blood vessels, BMP-2 is expressed in atheroprone regions and is down-regulated 
by statins in the endothelium [38-41]. Also, endothelium-derived BMPs are osteoinductive 
[42], thus they may also contribute to vascular calcification during the development of 
atherosclerotic plaques [11, 42]. A vascular BMP-2 was found to have an important role 
in vascular physiology in patients with primary pulmonary hypertension [43, 44], and to 
participate in smooth muscle cell chemotaxis in response to vascular injury [45]. Homocystein 
was found to increase BMP-2 expression by vascular smooth muscle cells [46]. Additionally, 
BMP2 expression is increased by exposure of endothelial cells to proinflammatory stimuli 
with consequent induction of a proinflammatory endothelial phenotype resulting in 
enhanced leukocyte adhesion to the endothelial surface in vitro [39, 47]. Increased levels 
of BMP-2 exert proinflammatory, proatherogenic effects by inducing oxidative stress and 
endothelial dysfunction and have been shown to promote plaque calcification by inducing 
an osteogenic phenotype in vascular smooth muscle cells [45, 48]. Based on these findings, 
we hypothesized that BMP-2 may be involved in vascular remodeling in patients with end-
stage renal disease and investigated association between their expression in blood vessels 
of recipients at time of transplantation, with the early and late posttransplant outcome. 
Artery wall evaluation at the time of transplantation may help to elucidate pathophysiologic 
relationship between donor and recipent.
In our cohort, BMP2 staining was recorded in the cytoplasm of endothelial cells of 
epigastric arteries. Statistically significant difference was recorded for BMP-2e expression 
between groups with lower expression intensity in DGF patients compared to IGF patients. 
BMP2 staining was recorded in the cytoplasm of muscular cells within the media layer 
of epigastric arteries. Although statistically significant difference in BMP-2m expression 
between DGF and IGF was not found, patients with DGF tend to have lower expression. There 
was no correlation of recipients’ gender, smoking status, hypertension, vascular disease, 
BMI or HLP on expression of either BMP-2m or BMP-2e. The effect of diabetes could not be 
analyzed due to low number of patients with this disease (4 patients).
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Postischemic events induce a continuum of complicated set of molecular, cellular, and 
extracellular responses that determine the function and the remodeling of the ischemic 
tissue [49]. Bone morphogenetic protein-7 (BMP-7) was found to decrease extent of acute 
renal injury in a rat model [50]. Also, exogenous BMP-7 has a neuroprotective effect after 
cerebral ischemia injury and promotes motor function recovery [51-53]. Less is known 
about the effects of BMP-2 in ischemic events. In a mouse model of acute myocardial 
infarction, BMP-2 reduced infarct size. Reduced rate of apoptotic cardiomyocytes both in the 
border zone of the infarcts and in the remote myocardium were found in mice treated with 
BMP-2. BMP-2 levels are increased in coronary artery disease patients with type 2 diabetes 
mellitus and correlate positively with the extent and complexity of coronary atherosclerotic 
disease as well as the degree of plaque calcification. These finding suggest that BMP-2 may 
be an important mediator of hyperglycemia-induced plaque progression and calcification 
[54]. In vitro, BMP-2 preserves cellular adenosine triphosphate stores, and decreases the 
rate of apoptosis. Additionally, BMP-2 induced Smad1/5/8 phosphorylation and protected 
adult cardiomyocytes from long-lasting hypoxia-induced cellular damage and oxidative 
stress avoiding activation of the transforming growth factor-β pathway, which is well known 
profibrotic factor [55]. If it is possible to translate these results in renal transplantation, 
it is possible that endogenous BMP-2 may ameliorate ischaemia-reperfusion injury in the 
early posttransplant period which is crucial for development of DGF. BMP family members, 
including BMP-2, act as proangiogenic factors, inducing endothelial cells proliferation, 
migration, and pseudotube formation in vitro and in vivo in a model of hindlimb ischemia. 
In vitro, recombinant BMP-2 activated BMP receptors, as witnessed by Id2 gene activation, 
increase proliferation, migration and pseudotube formation [56]. Also, BMP-2–muscle 
segment homeobox homologue (Msx2) signalling cascade can be activated by mural oxidative 
stress and inflammatory cytokines, suggesting that these signals participate in the arterial 
calcification as it is also observed in diabetic patients and animal model of chronic renal 
failure and the metabolic syndrome [57]. Finally, in patients with chronic kidney disease 
BMP-2 has recently been suggested to represent a link between oxidative stress and arterial 
stiffness due to vascular calcification [58]. Possible association with our results needs further 
investigations.
On the other hand, it was found that CD4+/CD8+ knockout mice are resistant to ischemia-
reperfusion injury [59, 60]. By influencing CD4+/CD8+ lymphocytes differentiation [14, 15], 
BMP-2 may have additional role in development of DGF, which needs to be investigated.
Clinical relevance of vascular calcifications is not clear [61-63].  Our results additionally 
contribute to the opinion that endothelial dysfunction may be even more important factor 
than changes within the medial layer of blood vessels. 
Some limitations of our study deserve future research. We did not assess the plasma 
levels of BMP-2.  Also, histological findings of epigastric artery may not be generalizable to 
other arterial territories. The cross-sectional design of the study also makes determining a 
causal relationship between BMP-2 and DGF challenging. Finally, this study was limited by a 
relatively small sample size. Further prospective studies are required to determine the role 
that BMP-2 levels have on clinical outcomes in renal transplant recipients.
This study provides the evidence that histologic materials obtained not only from 
donor, but also from recipient may have prognostic value after renal transplantation. We 
have shown that increased BMP-2 expression in endothelial, but not muscular cells of media 
layer of the epigastric artery of recipient, may predict development of DGF, as well as graft 
function at 1 year after transplantation. By expanding the knowledge about molecular events 
associated with development of DGF we may discover novel preventive and/or treatment 
options in renal transplantation.
Conclusion
In this study, lack of BMP-2 expression in endothelial cells is strongly associated with 
delayed graft function. Whether BMP-2 expression has beneficial effect on primary allograft 
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function by influencing ischaemia-reperfusion injury, modifying immunological response or 
both, or by some other mechanisms, remains to be elucidated.
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